A new precision oncology paper was published in Volume 17 of Oncotarget  titled “WIN-MTB-2024017 – WIN International Molecular Tumour Board: A 48-year-old female with multiple primary cancers.”

The study was led by Oncotarget Editor-in-Chief, Dr. Wafik S. El-Deiry, from the Worldwide Innovative Network (WIN) Association – WIN Consortium and Legorreta Cancer Centre at Brown University.

Patients who develop multiple primary cancers face unique diagnostic and treatment challenges because each tumour may have distinct biological characteristics requiring different therapeutic approaches.

Advances in genomic profiling and precision oncology now enable clinicians to better distinguish between independent tumours and recurrent disease while identifying molecular alterations that may guide individualised treatment strategies.

This case report demonstrates how an international molecular tumour board integrated comprehensive genomic data with multidisciplinary expertise to develop personalised recommendations for a patient with an exceptionally complex cancer history.

The case describes the clinical journey of a 48-year-old woman carrying a germline BRCA1 mutation who developed multiple primary cancers over nearly two decades, including breast cancer, basal cell carcinoma of the skin, high-grade serous ovarian carcinoma, colon cancer, and small bowel adenocarcinoma.

During this time, she underwent multiple surgeries, chemotherapy regimens, targeted therapy with the PARP inhibitor niraparib, and extensive molecular testing to characterise each malignancy.

Comprehensive genomic profiling revealed that although the patient’s cancers shared the inherited BRCA1 mutation, each tumour acquired additional somatic alterations that distinguished one malignancy from another.

The colon and small bowel tumours both carried an identical PIK3CA C420R mutation, supporting the conclusion that the small bowel tumour most likely represented recurrence of the previous colon cancer rather than an independent primary malignancy.

In contrast, the ovarian tumour demonstrated a different molecular profile, including a TP53 mutation and features consistent with high-grade serous ovarian carcinoma.

The investigators also identified a previously unreported BRCA1-STARD3 gene fusion in metastatic ovarian cancer tissue.

While the functional significance of this fusion has not yet been experimentally validated, the authors note that it represents a novel finding that may warrant further investigation.

The case illustrates how comprehensive molecular profiling can uncover uncommon genomic alterations that may provide new insights into cancer biology and future therapeutic opportunities.

An international Molecular Tumour Board (MTB), organised through the Worldwide Innovative Network (WIN) Consortium, reviewed the patient’s clinical history and molecular findings.

Rather than recommending a single treatment, the panel discussed several personalised management strategies that could be considered if the disease recurs.

These included combinations of targeted therapies directed at EGFR, PIK3CA, and BRCA1-associated pathways, immunotherapy combinations, anti-angiogenic therapy, aspirin for PIK3CA-mutated colorectal cancer, circulating tumour DNA monitoring, and investigational therapeutic vaccines targeting PIK3CA, STARD3, and mutant TP53.

The recommendations were intended to guide future clinical decision-making based on the patient’s molecular profile rather than represent established standards of care.

The experts also emphasised the importance of continued surveillance using regular imaging and circulating tumour DNA testing to monitor for recurrence.

They noted that repeated molecular profiling may help refine treatment decisions as tumours evolve and as new targeted therapies become available.

The case highlights how precision oncology can support ongoing clinical decision-making throughout a patient’s cancer journey.

“This case exemplifies the critical importance of clinical persistence and the transformative potential of precision medicine in complex oncology cases.”

According to the authors, molecular profiling should be viewed as an evolving clinical tool capable of revealing new therapeutic opportunities throughout the course of treatment.

They emphasise that patient management should remain dynamic, with treatment recommendations periodically reassessed as molecular technologies advance and knowledge of targetable cancer pathways continues to expand.

Overall, this case demonstrates how international molecular tumour boards can support personalised cancer care by combining detailed clinical evaluation with comprehensive genomic profiling.

Although many of the proposed therapeutic strategies remain investigational or off-label, the report highlights the growing role of precision oncology in helping clinicians develop individualised treatment plans for patients with rare and highly complex cancer histories.

Source: Impact Journals LLC